Bank Julius Baer & Co. Ltd Zurich Purchases New Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Bank Julius Baer & Co. Ltd Zurich purchased a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 65,070 shares of the medical equipment provider’s stock, valued at approximately $6,037,000. Bank Julius Baer & Co. Ltd Zurich owned 0.09% of Lantheus at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Raymond James Financial Inc. bought a new stake in Lantheus during the 4th quarter valued at approximately $36,183,000. Groupama Asset Managment bought a new stake in Lantheus during the 3rd quarter valued at approximately $439,000. Swedbank AB boosted its position in Lantheus by 53.3% during the 4th quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider’s stock valued at $99,054,000 after acquiring an additional 385,000 shares in the last quarter. Keybank National Association OH bought a new stake in Lantheus during the 4th quarter valued at approximately $27,526,000. Finally, Janus Henderson Group PLC boosted its position in Lantheus by 7.7% during the 3rd quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider’s stock valued at $393,844,000 after acquiring an additional 257,022 shares in the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Trading Up 6.1 %

LNTH stock opened at $106.34 on Monday. The stock has a market capitalization of $7.28 billion, a PE ratio of 17.69 and a beta of 0.38. Lantheus Holdings, Inc. has a 12-month low of $56.44 and a 12-month high of $126.89. The stock’s 50 day simple moving average is $90.71 and its 200 day simple moving average is $96.82.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.23). The business had revenue of $391.11 million during the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. On average, research analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have weighed in on LNTH shares. StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Truist Financial boosted their price target on Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. JMP Securities reissued a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a research report on Tuesday, January 14th. Finally, The Goldman Sachs Group began coverage on Lantheus in a research report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price target on the stock. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $132.86.

Insider Activity at Lantheus

In related news, Director Mary Anne Heino sold 53,107 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the transaction, the director now directly owns 440,399 shares of the company’s stock, valued at approximately $41,551,645.65. This represents a 10.76 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director James H. Thrall sold 1,000 shares of the business’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the sale, the director now owns 33,207 shares of the company’s stock, valued at approximately $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.50% of the stock is currently owned by insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.